Published in Mult Scler on December 09, 2013
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
Demographic and clinical features of neuromyelitis optica: A review. Mult Scler (2015) 1.14
Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm (2015) 1.04
Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol (2015) 0.83
Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population. BMC Neurol (2015) 0.75
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain (1980) 3.27
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Multiple sclerosis: a comparison of the latent periods of different populations. Neuroepidemiology (1993) 1.94
Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry (1998) 1.84
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology (2003) 1.73
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol (1997) 1.72
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler (2015) 1.72
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. J Neurol Sci (2009) 1.52
Neuromyelitis optica and pregnancy. Neurology (2012) 1.49
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry (1997) 1.44
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry (2013) 1.42
Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler (2008) 1.41
[Familial epilepsy seizure disclosing long QT syndrome]. Rev Neurol (Paris) (1996) 1.39
Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology (2012) 1.25
Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology (2011) 1.23
Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler (2009) 1.15
Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler (2009) 1.15
Clinical outcomes assessment in multiple sclerosis. Ann Neurol (1996) 1.11
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology (2009) 1.05
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology (2012) 1.05
Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. AJNR Am J Neuroradiol (2012) 1.02
Diffusion tensor-MRI evidence for extra-axonal neuronal degeneration in caudate and thalamic nuclei of patients with multiple sclerosis. AJNR Am J Neuroradiol (2012) 0.99
Dot-blot immunodetection of antibodies against GM1 and other gangliosides on PVDF-P membranes. J Immunol Methods (1993) 0.97
Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler (2012) 0.97
[Multiple sclerosis and pregnancy]. Rev Neurol (Paris) (2006) 0.92
[Causes of paralysis of the hypoglossal nerve. Apropos of 32 cases]. Presse Med (1990) 0.92
DNA polymorphism related to HLA-DR2 Dw2 in patients with narcolepsy. Immunogenetics (1985) 0.91
Bone marrow CD34+/B220+ progenitors target the inflamed brain and display in vitro differentiation potential toward microglia. FASEB J (2006) 0.91
Danazol-induced hepatocellular carcinoma. QJM (2003) 0.90
Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology (2010) 0.90
[Anatomo-clinical study of a case of topographic confabulation (or delusion)]. Cortex (1980) 0.88
Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology (2011) 0.87
Aneurysmal bone cyst of the cervical spine: report of a case investigated by computed tomographic scanning and treated by a two-stage surgical procedure. Neurosurgery (1982) 0.86
[Oculo-palatal myoclonus and multiple sclerosis]. Rev Neurol (Paris) (1990) 0.85
High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler (2011) 0.85
Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. Neurology (1998) 0.85
[Spatial disorientation. Report of 5 cases (author's transl)]. Rev Neurol (Paris) (1981) 0.85
Multiple sclerosis and epileptic seizures. Mult Scler (2010) 0.85
[18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol (2000) 0.84
Course of valvular strands in patients with stroke: cooperative study with transesophageal echocardiography. Am Heart J (1998) 0.82
[South-Eastern France, a high risk area for multiple sclerosis?]. Presse Med (1987) 0.82
Primary angiitis of the central nervous system: response to mycophenolate mofetil. J Neurol Neurosurg Psychiatry (2009) 0.82
A pyramidal approach for automatic segmentation of multiple sclerosis lesions in brain MRI. Comput Med Imaging Graph (1999) 0.82
Unusual ocular motor findings in multiple sclerosis. J Neurol Sci (2006) 0.82
Improvements to a simple Markov model of the natural history of multiple sclerosis. I. Short-term prognosis. Neuroepidemiology (1987) 0.81
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant (2009) 0.81
Brain structures selectively targeted by canine distemper virus in a mouse model infection. J Neuropathol Exp Neurol (1993) 0.81
Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. J Neurol Neurosurg Psychiatry (1986) 0.81
A Markov model of the natural history of multiple sclerosis. Neuroepidemiology (1985) 0.80
[Long-lasting and isolated Uhthoff's phenomenon after effort preceding multiple sclerosis]. Rev Neurol (Paris) (2009) 0.80
Korsakoff's syndrome as the initial presentation of multiple sclerosis. J Neurol (1991) 0.80
Thalamic stroke and congenital factor V deficiency. Stroke (1991) 0.79
[Course of visual evoked potentials in multiple sclerosis. Electro-clinical correlations and pathophysiological considerations in 25 patients (author's transl)]. Rev Neurol (Paris) (1981) 0.79
Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics (1998) 0.78
Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases. J Neurol Neurosurg Psychiatry (2010) 0.78
Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis. J Neurol Neurosurg Psychiatry (1995) 0.77
Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology (2006) 0.77
[Idiopathic cranial polyneuropathies]. Rev Neurol (Paris) (1992) 0.77
Nicotine-sensitive myasthenia gravis. Lancet (1994) 0.77
The acute deafness of definite multiple sclerosis: BAEP patterns. Electroencephalogr Clin Neurophysiol (1985) 0.77
[Paralysis of downward gaze and chronic global amnesia as a result of a bilateral thalamo-subthalamic lesion]. Rev Neurol (Paris) (1986) 0.77
[Side effects of azathioprine (Imurel). Apropos of 313 patients treated for multiple sclerosis. Review of the literature]. Therapie (1985) 0.77
[Intramedullary subependymoma of the cervical spinal cord. Review of the literature a propos of a case]. Neurochirurgie (1997) 0.76
[Bilateral deafness, an initial manifestation of meningeal carcinomatosis]. Rev Neurol (Paris) (1992) 0.76
HLA-DR2 negative narcolepsy. J Neurol Neurosurg Psychiatry (1987) 0.76
Design of a European multicenter study dedicated to the evaluation of the EDMUS system: EVALUED. European Database for MUltiple Sclerosis. EVALUation of the EDMUS system. Mult Scler (1999) 0.76
Magnetic resonance imaging contribution to the diagnosis of spinal cord compression by a subdural arachnoid cyst. Neuroradiology (1991) 0.76
[Treatment of multiple sclerosis by Azathioprine. About 77 cases studied during 10 years (author's transl)]. Rev Neurol (Paris) (1978) 0.75
[Dementia and psychiatric disorders in Kufs disease]. Rev Neurol (Paris) (1990) 0.75
Acute acquired toxoplasmosis causing neuroptico-meningoencephalitis in an immunocompetent boy. J Neurol Neurosurg Psychiatry (1985) 0.75
Nicotine-sensitive myasthenia gravis. Lancet (1995) 0.75
Familial hypokalaemic periodic paralysis: prevention of paralytic attacks with lithium gluconate. J Neurol Neurosurg Psychiatry (1991) 0.75
[Paralysis of abdominal muscles caused by Lyme disease]. Rev Neurol (Paris) (1993) 0.75
[Sclerotic plaques and hepatitis B vaccination in adults: the situation in 2004. Response]. Rev Neurol (Paris) (2005) 0.75
Simultaneous medullar and cutaneous revelation of a cutaneomeningospinal angiomatosis. Eur Neurol (1999) 0.75
[Can the prognosis of multiple sclerosis be predicted?]. Pathol Biol (Paris) (2000) 0.75
[Letter: Effectiveness of L-tryptophan on Parkinsonian tremor. Preliminary study]. Nouv Presse Med (1976) 0.75
[Nicotine and worsening myasthenia]. Rev Neurol (Paris) (1997) 0.75
P.O.E.M.S. syndrome with complete recovery after treatment of a solitary plasmocytoma. Clin Neurol Neurosurg (1991) 0.75
[Conference at Salpêtrière Hospital. January 1990. Progressive motor incoordination in a man with late partial epilepsy]. Rev Neurol (Paris) (1992) 0.75
[Hypersensitivity to azathioprine can simulate an aggravation of myasthenia]. Therapie (1998) 0.75
[Treatment of Wilson's disease with zinc. 5 cases]. Rev Neurol (Paris) (1993) 0.75
[Painful sequelae of Wallenberg's syndrome]. Presse Med (1992) 0.75
[Multiple sclerosis: spontaneous course, natural history]. Rev Neurol (Paris) (2001) 0.75
[A brachial form of motor neuropathy caused by lead poisoning]. Rev Neurol (Paris) (1998) 0.75
[Arnold-Chiari malformation in adults. Development of diagnostic conditions since the availability of MRI]. Rev Neurol (Paris) (1993) 0.75
[MRI in the study of multiple sclerosis]. Rev Neurol (Paris) (1997) 0.75
[Confusional syndrome: diagnostic trends]. Rev Prat (1998) 0.75
[Results of cerebrospinal fluid examination. Significance of results (normal, hemorrhagic, purulent, lymphocytic, inflammatory, albumin-cytologic dissociation]. Rev Prat (1990) 0.75
Cholera toxin beta subunit induces the differentiation of human medulloblastoma cell line DEV in a neuronal pathway. Eur J Neurosci (1994) 0.75
[Pseudomyasthenic pre-Basedow ophthalmoplegia]. Rev Neurol (Paris) (1990) 0.75